FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1277-1279 September 25, 2003 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Black, D. M. Related Article by Finkelstein, J. S. PubMed Citation

The past 10 years have witnessed tremendous advances in our ability to treat osteoporosis. The old mainstays of therapy, estrogen and calcitonin, have fallen out of favor because of concern about long-term safety or lack of efficacy. In their wake have come a selective estrogen-receptor modulator (raloxifene), bisphosphonates (alendronate and risedronate), and most recently, parathyroid hormone. Raloxifene and the bisphosphonates belong to the class of antiresorptive drugs: by inhibiting bone resorption, they prevent further bone loss, and since bone formation and further mineralization continue for some time, these agents also result in moderate increases in bone mineral density. In contrast, . . . [Full Text of this Article]

Source Information

From the Endocrine Research Unit, Division of Endocrinology, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minn.

This editorial was published at www.nejm.org on September 20, 2003.

Related Letters:

Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis
Vegni F. E., Corradini C., Privitera G., Sugiyama T., Tanaka H., Kawai S., Miller P. D., Fuller K. E., Black D. M., Bilezikian J., Rosen C. J., the PaTH (Parathyroid Hormone and Alendronate) Study Investigators , Finkelstein J. S., Neer R. M.
Extract | Full Text | PDF  
N Engl J Med 2004; 350:189-192, Jan 8, 2004. Correspondence

This article has been cited by other articles:

• Lorenzo, J., Horowitz, M., Choi, Y. (2008). Osteoimmunology: Interactions of the Bone and Immune System. Endocr. Rev. 29: 403-440 [Abstract] [Full Text]  
• Potts, J. T (2005). Parathyroid hormone: past and present. J Endocrinol 187: 311-325 [Abstract] [Full Text]  
• Vegni, F. E., Corradini, C., Privitera, G., Sugiyama, T., Tanaka, H., Kawai, S., Miller, P. D., Fuller, K. E., Black, D. M., Bilezikian, J., Rosen, C. J., the PaTH (Parathyroid Hormone and Alendronate) Stu, , Finkelstein, J. S., Neer, R. M. (2004). Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis. NEJM 350: 189-192 [Full Text]